Alder BioPharmaceuticals Inc. (NASDAQ:ALDR)’s share price traded down 1.2% on Tuesday . The stock traded as low as $32.65 and last traded at $32.92, with a volume of 404,167 shares trading hands. The stock had previously closed at $33.31.

Several equities analysts have recently weighed in on the company. Jefferies Group reissued a “buy” rating and set a $61.00 price target on shares of Alder BioPharmaceuticals in a report on Tuesday, July 19th. Brean Capital reaffirmed a “buy” rating on shares of Alder BioPharmaceuticals in a report on Saturday, April 30th. Finally, Zacks Investment Research raised Alder BioPharmaceuticals from a “hold” rating to a “buy” rating and set a $29.00 target price on the stock in a report on Wednesday, July 20th. One investment analyst has rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. The company currently has an average rating of “Buy” and an average target price of $44.00.

The company’s 50 day moving average price is $29.02 and its 200-day moving average price is $25.72. The firm’s market cap is $1.67 billion.

Alder BioPharmaceuticals (NASDAQ:ALDR) last released its quarterly earnings results on Tuesday, July 26th. The biopharmaceutical company reported ($0.79) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.75) by $0.04. The business had revenue of $0.11 million for the quarter, compared to analyst estimates of $1.14 million. During the same quarter in the prior year, the company earned ($0.46) earnings per share. The company’s revenue was up 112900.0% on a year-over-year basis. Equities analysts predict that Alder BioPharmaceuticals Inc. will post ($2.76) EPS for the current year.

In other Alder BioPharmaceuticals news, VP Jeffrey T. L. Smith sold 3,000 shares of Alder BioPharmaceuticals stock in a transaction on Monday, August 15th. The shares were sold at an average price of $31.17, for a total value of $93,510.00. Following the transaction, the vice president now directly owns 3,000 shares of the company’s stock, valued at $93,510. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider John A. Latham sold 6,401 shares of Alder BioPharmaceuticals stock in a transaction on Friday, May 27th. The stock was sold at an average price of $30.05, for a total transaction of $192,350.05. Following the completion of the transaction, the insider now directly owns 248,601 shares in the company, valued at $7,470,460.05. The disclosure for this sale can be found here.

A hedge fund recently raised its stake in Alder BioPharmaceuticals stock. Wells Fargo & Company MN boosted its stake in Alder BioPharmaceuticals Inc. (NASDAQ:ALDR) by 290.6% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 269,774 shares of the biopharmaceutical company’s stock after buying an additional 200,707 shares during the period. Wells Fargo & Company MN owned about 0.62% of Alder BioPharmaceuticals worth $8,911,000 at the end of the most recent reporting period.

Alder Biopharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company discovers, develops and focuses to commercialize therapeutic antibodies with the potential to transform current treatment paradigms. The Company has developed an antibody platform designed to select antibodies that have the potential to maximize efficacy, as well as speed of onset and durability of therapeutic response.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.